{"id":967997,"date":"2026-05-28T08:05:53","date_gmt":"2026-05-28T12:05:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"},"modified":"2026-05-28T08:05:53","modified_gmt":"2026-05-28T12:05:53","slug":"artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","title":{"rendered":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference"},"content":{"rendered":"
\n

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT.<\/p>\n

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors<\/a> section of Artiva\u2019s website. The archived audio webcast will remain available for replay on Artiva\u2019s website for 90 days.<\/p>\n

\n About Artiva Biotherapeutics
<\/strong>Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva\u2019s lead program, AlloNK\u00ae<\/sup> (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sj\u00f6gren\u2019s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell\u2019s NK cell manufacturing technology and programs.<\/p>\n

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva regarding the potential benefits, accessibility, effectiveness, safety and design of AlloNK\u00ae<\/sup>; Artiva’s plan to initiate a registrational Phase 3 trial for AlloNK in 2026; and Artiva’s participation in the 2026 Jefferies Global Healthcare Conference. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks inherent in developing product candidates and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including the section titled \u201cRisk Factors\u201d in Artiva’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n Contacts<\/strong><\/p>\n

Investors<\/strong>
\n
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com<\/a>
<\/a>
Media<\/strong>
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com<\/a><\/p>\n

Source: Artiva Biotherapeutics, Inc.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva\u2019s website. The archived audio webcast will remain available for replay on Artiva\u2019s website for 90 days. About Artiva BiotherapeuticsArtiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell … <\/p>\n

Continue reading “Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-967997","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva\u2019s website. The archived audio webcast will remain available for replay on Artiva\u2019s website for 90 days. About Artiva BiotherapeuticsArtiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell … Continue reading "Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T12:05:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference\",\"datePublished\":\"2026-05-28T12:05:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\"},\"wordCount\":582,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\",\"name\":\"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=\",\"datePublished\":\"2026-05-28T12:05:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk","og_description":"SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva\u2019s website. The archived audio webcast will remain available for replay on Artiva\u2019s website for 90 days. About Artiva BiotherapeuticsArtiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell … Continue reading \"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-28T12:05:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference","datePublished":"2026-05-28T12:05:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"},"wordCount":582,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/","name":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=","datePublished":"2026-05-28T12:05:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzY0OCM3NjI0Mjk3IzIyOTE5MDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=967997"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/967997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=967997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=967997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=967997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}